文献速递心力衰竭与心肌病

细胞毒性CD8+ T细胞中PD-1抑制加重压力负荷诱导的心脏损伤

Inhibition of Programmed Cell Death-1 in Cytotoxic CD8+ T Cells Exacerbates Pressure Overload-Induced Cardiac Injury.
PubMed 文献 · Circulation · 2026-09-01

该研究在小鼠横向主动脉缩窄(TAC)模型中探讨抗PD-1抗体加重心脏重塑和心力衰竭的机制。结果显示抗PD-1抗体或T细胞/CD8+ T细胞特异性Pdcd1缺失(而非髓系特异性缺失)加重TAC诱导的心肌病和心衰,其机制涉及CXCL9/CXCL10-CXCR3轴招募CXCR3+ CD8+ T细胞,通过颗粒酶B/穿孔素损伤心肌细胞线粒体复合物I。遗传或药理阻断颗粒酶B和CXCR3可逆转上述加重效应。

要点

  • 抗PD-1抗体或CD8+ T细胞PD-1缺失加重TAC诱导的心衰。
  • CXCL9/CXCL10-CXCR3轴招募CXCR3+ CD8+ T细胞至心脏。
  • 颗粒酶B/穿孔素损伤心肌细胞线粒体复合物I促凋亡。

核心结论

  • 抗PD-1抗体通过CXCL9/CXCL10介导的趋化作用增强TAC条件下CXCR3+ CD8+ T细胞心肌浸润,其来源的颗粒酶B和穿孔素损伤线粒体呼吸链复合物功能导致心肌细胞凋亡,从而加重TAC诱导的心肌病和心衰。
  • CXCL9/CXCL10-CXCR3+ CD8+ T细胞轴可能是对抗抗PD-1抗体相关心脏毒性的有前景靶点。

研究设计与样本

  • 研究使用抗PD-1抗体处理的 mice;T细胞、髓系和CD8+ T细胞特异性Pdcd1敲除 mice;Cxcr3敲除 mice;颗粒酶B(Gzmb)敲除 mice,结合流式细胞术、Western blotting、免疫荧光染色、药理学方法和 bulk RNA-sequencing 分析。
  • 模型为横向主动脉缩窄(TAC)诱导的心脏重塑和心衰。

主要发现

  • 给予抗PD-1抗体、T细胞或CD8+ T细胞特异性Pdcd1缺失(而非髓系特异性Pdcd1敲除)加重TAC诱导的心肌病和心衰。
  • PD-1阻断或缺失增加CXCR3+ CD8+ T细胞心肌浸润,导致颗粒酶B/穿孔素介导的心肌细胞线粒体复合物I损伤,加重TAC诱导的心脏损伤和心衰。
  • TAC增强的心脏成纤维细胞来源CXCL9/CXCL10与CXCR3+ CD8+ T细胞之间的趋化作用是PD-1阻断或缺失条件下招募CXCR3+ CD8+ T细胞的驱动力。
  • 遗传缺失或药理学阻断颗粒酶B和CXCR3可挽救抗PD-1抗体或T细胞特异性Pdcd1缺失所致的TAC诱导心肌病加重。

临床怎么用

  • 对于接受抗PD-1抗体治疗且存在心血管基础疾病的患者,需关注心衰风险,机制上CD8+ T细胞来源的颗粒酶B和CXCR3轴可能参与心脏毒性。
  • CXCL9/CXCL10-CXCR3+ CD8+ T细胞轴或颗粒酶B可能作为减轻抗PD-1抗体相关心脏毒性的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of anti-programmed cell death-1 (PD-1) antibody increases heart failure (HF) risk in patients with cancer with preexisting cardiovascular conditions. However, the underlying mechanism remains incompletely understood. METHODS: To evaluate the effects of anti-PD-1 antibody on transverse aortic constriction (TAC)-induced cardiac remodeling and HF, anti-PD-1 antibody-treated mice; T cell-, myeloid-, and CD8+ T cell-specific Pdcd1 knockout; C-X-C motif chemokine receptor 3 (Cxcr3) knockout; and granzyme B (Gzmb) knockout mice combined with flow cytometry, Western blotting, immunofluorescence staining, pharmacological approaches, and bulk RNA-sequencing analyses were used. RESULTS: Administration of anti-PD-1 antibody, T cell-, or CD8+ T cell-specific Pdcd1 deletion, but not myeloid-specific Pdcd1 knockout, aggravated TAC-induced cardiomyopathy and HF in mice. Mechanistically, PD-1 blockade or deletion increased myocardial infiltration of CXCR3+ CD8+ T cells, leading to granzyme B/perforin-mediated impairment of cardiomyocyte mitochondrial complex I to exacerbate TAC-induced cardiac injury and HF. TAC-enhanced chemotaxis, between cardiac fibroblast-derived CXCL9/CXCL10 and CXCR3+ CD8+ T cells, was a driving force for recruiting CXCR3+ CD8+ T cells under the conditions of PD-1 blockade or deletion. The worsened TAC-induced cardiomyopathy caused by anti-PD-1 antibody or T cell-specific Pdcd1 deletion was rescued by genetic deletion or pharmacological blockade of granzyme B and CXCR3. CONCLUSIONS: Anti-PD-1 antibody enhances myocardial infiltration of CXCR3+ CD8+ T cells under TAC condition through CXCL9/CXCL10-mediated chemotaxis. The increased granzyme B and perforin likely derived from CD8+ T cells impair function of mitochondrial respiratory chain complexes to cause cardiomyocyte apoptosis, thereby exacerbating TAC-induced cardiomyopathy and HF. CXCL9/CXCL10-CXCR3+ CD8+ T cell axis may represent a promising target for combating anti-PD-1 antibody-associated cardiotoxicity.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wu MM, Sun Y, Zhang Y, et al. Inhibition of Programmed Cell Death-1 in Cytotoxic CD8+ T Cells Exacerbates Pressure Overload-Induced Cardiac Injury. Circulation. 2026. PMID: 42677471. doi:10.1161/CIRCULATIONAHA.125.074024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。